Prognostic factors of morbidity-mortality of isolated tricuspid valve surgery (ITVS) - 09/01/21
Résumé |
Introduction |
Moderate and severe TR is a prognostic marker of mortality independently from right ventricular dysfunction, pulmonary hypertension and left ventricular dysfunction. The survival benefit of ITVS is controversial.
Purpose |
The aim of this study is to define the clinical and paraclinical criteria associated with morbidity-mortality of ITVS.
Methods |
We conducted a single-centre, retrospective study of 69 patients who underwent an ITVS at Marseille University Hospital from 2008 to 2018. Combined left-heart surgery and congenital cardiopathy were excluded. The primary outcome (PO) is composite including death and rehospitalization for acute decompensated heart failure within a year after surgery.
Results |
Nineteen patients were treated for secondary tricuspid regurgitation (TR) (15 TR following left-sided valvulopathy and 4 TR caused by chronic atrial fibrillation (AF)). Forty-four had an operation for primary TR (36.5% of total TR were endocarditis). Mean patient follow-up was 44.5 months. Thirty-seven % of patients with secondary TR met the PO versus 9% of others (P=0.011). Preoperative signs of chronic right heart failure (NYHA, congestive signs, anaemia and hyponatremia) were significantly linked with our PO. Right ventricular systolic pressure collected by preoperative right heart catheterization was a marker of unfavourable postoperative prognosis, confirmed by multivariate analysis (P=0.006). Survival was worse for secondary TR (two years after surgery, 50% of patients with secondary TR were still alive and had not been readmitted versus 75% of others, P=0.01).
Conclusion |
Isolated surgery of functional TR, whether caused by pulmonary hypertension secondary to left heart disease or due to right atrial dilatation (linked to AF) without a downstream obstacle, had a high morbidity-mortality risk in the short-term. Right heart catheterization may help in targeting high-risk surgical patients with secondary TR for percutaneous treatment.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 1
P. 71 - janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.